Denver, CONCT05199688Now EnrollingIRB Ready

Neuromyelitis Optica Spectrum Disorder Clinical Trial in Denver, CO

Access cutting-edge neuromyelitis optica spectrum disorder treatment through this clinical trial at a research site in Denver. Study-provided care at no cost to qualified participants.

Sponsored by Hoffmann-La Roche

Quick Self-Assessment

See if you qualify for this Denver location

Preparing your pre-screening questions…

Expert Care in Denver

Access neuromyelitis optica spectrum disorder specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related neuromyelitis optica spectrum disorder treatment provided free

Apply for This Denver Location

Check if you qualify for this neuromyelitis optica spectrum disorder clinical trial in Denver, CO

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Denver

    Convenient for CO residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Denver site if eligible
  4. 4Begin participation

About This Neuromyelitis Optica Spectrum Disorder Study in Denver

This study will primarily evaluate the pharmacokinetics of satralizumab in pediatric patients aged 2-11 years with anti-aquaporin-4 (AQP4) antibody seropositive neuromyelitis optica spectrum disorder (NMOSD). Efficacy, safety, tolerability, and pharmacodynamics will be evaluated in a descriptive manner, given the small number of patients who will be enrolled in this study.

Sponsor: Hoffmann-La Roche

Who Can Participate

Inclusion Criteria

Age at screening 2-11 years, inclusive
Body weight at screening \>=10 kg
For female patients of childbearing potential (postmenarchal): agreement to either remain completely abstinent (refrain from heterosexual intercourse) or to use a reliable means of contraception
Diagnosed as having NMOSD with AQP4 antibody seropositive status as defined by the Wingerchuk 2015 criteria Clinical evidence of at least one documented attack (including first attack) in the last year prior to screening
Neurological stability for \>=30 days prior to both screening and baseline
Expanded Disability Status Scale (EDSS) 0 to 6.5
For patients receiving a baseline immunosuppressant treatment and planning to continue on these therapies, treatment must be at stable dose for 4 weeks prior to baseline

Exclusion Criteria

Pregnancy or lactation
Evidence of other demyelinating disease mimicking NMOSD
Active or presence of recurrent bacterial, viral, fungal, mycobacterial infection, or other infection at baseline
Evidence of chronic active hepatitis B or C
Evidence of untreated latent or active tuberculosis (TB)
Receipt of a live or live-attenuated vaccine within 6 weeks prior to baseline
History of severe allergic reaction to a biologic agent

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Denver?

Yes, this clinical trial (NCT05199688) has an active research site in Denver, CO that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Neuromyelitis Optica Spectrum Disorder Treatment Options in Denver, CO

If you're searching for neuromyelitis optica spectrum disorder treatment options in Denver, CO, this clinical trial (NCT05199688) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Denver research site is actively enrolling participants for this clinical trial. You'll receive care from experienced neuromyelitis optica spectrum disorder specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all neuromyelitis optica spectrum disorder clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Embolism Trials in Denver, CO

See all pulmonary embolism clinical trials recruiting in Denver — not just this study.

Browse Pulmonary Embolism Trials in Denver →

Browse More Trials by Condition

Pulmonary Embolism TrialsInterstitial Cystitis TrialsNeuromyelitis Optica TrialsAll Conditions →

Ready to Join in Denver?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Denver, CO